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Methods Patients were randomly assigned to receive doc-
etaxel plus S-1 or S-1 alone. The docetaxel plus S-1 group 
received docetaxel on day 1 and oral S-1 on days 1–14 of 
a 21-day cycle. The S-1 alone group received oral S-1 on 
days 1–28 of a 42-day cycle. The primary end point was 
overall survival.
Results Of the 639 patients enrolled, 635 were eligible 
for analysis. The median overall survival was 12.5 months 
in the docetaxel plus S-1 group and 10.8 months in the 
S-1 alone group (p = 0.032). The median progression-free 
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ment for advanced gastric cancer in East Asia. This phase 
III study was designed to evaluate the potential benefits of 
adding docetaxel to S-1 without a platinum compound in 
patients with advanced gastric cancer.
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survival was 5.3 months in the docetaxel plus S-1 group 
and 4.2 months in the S-1 alone group (p = 0.001). As for 
adverse events, neutropenia was more frequent in the doc-
etaxel plus S-1 group, but remained manageable.
Conclusion As first-line treatment for advanced gastric 
cancer, docetaxel plus S-1 significantly improves median 
overall and progression-free survival as compared with S-1 
alone. (ClinicalTrials.gov number: NCT00287768).
Keywords Advanced gastric cancer · Chemotherapy · 
S-1 · Docetaxel
Introduction
Gastric cancer is the second most common cause of can-
cer death worldwide. The only potentially curative treat-
ment for patients with gastric cancer is surgical resection. 
However, regional and distant recurrence often occurs 
after surgery. The standard treatment for advanced or 
recurrent gastric cancer is chemotherapy, hoping to pro-
long survival.
In the late 1990s, cisplatin plus 5-fluorouracil was glob-
ally accepted as a benchmark treatment for advanced gas-
tric cancer and has since been used in many controlled clin-
ical trials of new chemotherapeutic regimens (Ohtsu et al. 
2003; Van Cutsem et al. 2006; Al-Batran et al. 2008; Cun-
ningham et al. 2008; Boku et al. 2009). However, cisplatin 
has several important drawbacks, including high incidences 
of nausea, vomiting (Kris et al. 2006), and renal toxicity 
(Fillastre and Raguenez-Viotte 1989; Arany and Safirstein 
2003) the need for admission to receive therapy, and other 
adverse events negatively affecting the quality of life of 
patients. Cisplatin is contraindicated in patients with poor 
renal function. The development of combination chemo-
therapy regimens that do not include platinum compounds 
has thus been awaited as a new option for the first-line 
treatment for advanced gastric cancer.
During the planning phase of this trial, docetaxel (Mai 
et al. 1999; Graziano et al. 2000; Mavroudis et al. 2000; 
Bang et al. 2002) and S-1, an oral preparation combin-
ing tegafur (a prodrug of fluorouracil) with gimeracil and 
oteracil potassium in a molar ratio of 1:0.4:1, were shown 
to be effective as monotherapy against advanced gas-
tric cancer (Sakata et al. 1998; Shirasaka 2009). In West-
ern countries, a phase III study comparing docetaxel plus 
cisplatin/5-fluorouracil with cisplatin plus 5-fluoroura-
cil was ongoing in patients with advanced gastric cancer 
(V325 study). In Japan, S-1 had become the most widely 
used drug for the treatment for advanced gastric can-
cer, and phase III studies of S-1 plus cisplatin versus S-1 
alone (SPIRITS trial: Koizumi et al. 2008) and S-1 plus 
irinotecan versus S-1 alone (TOP-002 trial: Narahara et al. 
2011) were ongoing.
Phase II and phase I/II studies of S-1 plus docetaxel 
in Japanese patients with advanced gastric cancer have 
reported response rates of 56.2 and 45.7 %, with median 
survival times of 14.3 and 14.0 months, respectively 
(Yoshida et al. 2006; Yamaguchi et al. 2006). Although the 
dose of docetaxel (40 mg per square meter of body surface 
area) was lower than that used in Western countries, treat-
ment was well tolerated in both studies, suggesting that S-1 
plus docetaxel is a promising new regimen for the chemo-
therapeutic management of advanced gastric cancer. To 
confirm and extend these results, we performed a controlled 
study comparing S-1 plus docetaxel with S-1 alone as first-
line chemotherapy for advanced gastric cancer, without the 
use of any platinum compounds.
Patients and methods
The Japan Clinical Cancer Research Organization (JAC-
CRO) GC-03 study (START trial) was a multicenter, pro-
spective, randomized, phase III open-label trial performed 
by the JACCRO and the Korean Cancer Study Group 
(KCSG) ("Appendix"). Patients were registered and fol-
lowed up using the FLADS® system (Takt Systems, Inc., 
Tokyo, Japan), a Web-based registration and data collection 
system for clinical trials of anticancer therapy.
This study was performed in accordance with the decla-
ration of Helsinki and the ethical guidelines and regulations 
of each country. The protocol was approved by the ethics 
committees of each center before the initiation of enroll-
ment. An independent Response and Safety Evaluation 
Committee reviewed all efficacy and safety data.
Written informed consent was obtained from all patients 
before enrollment in the study. Eligible patients had to 
satisfy the following criteria: an expected survival of 
3 months or longer; no prior chemotherapy; an age of 20 to 
younger than 80 years; an Eastern Cooperative Oncology 
Group performance status of zero or one; a histologically 
confirmed diagnosis of unresectable or advanced gastric 
adenocarcinoma (including adenocarcinoma of the gas-
troesophageal junction) or unresectable recurrence; ability 
to orally intake food and liquids; either measurable or non-
measurable lesions as defined by the Response Evaluation 
Criteria in Solid Tumors (RECIST), version 1.0 (Therasse 
et al. 2000); and adequate organ functions.
Patients were excluded if they had any of the following 
conditions: another active cancer; severe ascites requiring 
drainage; grade 2 or severer peripheral neuropathy, pul-
monary fibrosis, or interstitial pneumonitis; or a history of 
chemotherapy or radiotherapy for advanced gastric cancer.
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Treatment and testing
Patients were stratified according to institutions and 
whether they had measurable or non-measurable lesions 
and were then randomly assigned to receive docetaxel plus 
S-1 or S-1 alone. Treatment was continued until the onset 
of progressive disease, the development of toxicity meeting 
the criteria for drug withdrawal, or the withdrawal of con-
sent by the patient. The docetaxel plus S-1 group received 
docetaxel (40 mg per square meter of body surface area) as 
a 1-h intravenous infusion on day 1 and oral S-1 on days 
1–14 of a 21-day cycle. The daily dose of S-1 (given in 
two divided doses) was assigned according to body surface 
area as follows: <1.25 m2, 80 mg daily; ≥1.25–<1.5 m2, 
100 mg daily; and ≥1.5 m2, 120 mg daily. The S-1 alone 
group received the same dose levels of S-1 as the docetaxel 
plus S-1 group, similarly assigned according to body sur-
face area, on days 1–28 of a 42-day cycle. In the event 
of predefined toxic events, protocol-specified treatment 
modifications were permitted. Adverse events were graded 
according to the National Cancer Institute Common Toxic-
ity Criteria for Adverse Events (NCI-CTCAE), version 3.0.
Statistical analysis
The primary end point was overall survival, defined as the 
interval between enrollment and death from any cause. Sec-
ondary end points were progression-free survival, response 
rate, and safety. Response rates were based on the assess-
ment of response by the investigators at each center and 
were reviewed by the Central Review Board of JACCRO; 
response was evaluated in accordance with RECIST, ver-
sion 1.0.
The overall survival and progression-free survival were 
calculated on the basis of an intent-to-treat analysis, and 
response rates were calculated on the basis of the per-pro-
tocol set (Fig. 1). Survival curves were calculated by the 
Kaplan–Meier method, and differences between groups 
were compared with the use of log-rank tests. In two previ-
ous phase II studies, the median survival times of patients 
with previously untreated advanced gastric cancer who 
received S-1 alone were 250 and 207 days (Sakata et al. 
1998; Koizumi et al. 2000), respectively. Two phase II stud-
ies of docetaxel plus S-1 reported median survival times of 
434 and 427 days, respectively (Yoshida et al. 2006; Yama-
guchi et al. 2006). On the basis of these results, the median 
survival time was assumed to be 400 days in the docetaxel 
plus S-1 group and 300 days in the S-1 alone group. We 
estimated that a total enrollment of 628 patients was needed 
for the study to have a 90 % power to detect a difference in 
overall survival between the treatment groups with a two-
sided alpha value of 0.05, assuming an enrollment period 
of 3 years, a follow-up period of 2 years, and a 10 % exclu-
sion rate due to ineligibility. We planned an interim analy-
sis after 377 deaths had been confirmed to decide whether 
to terminate the study.
This study was registered with ClinicalTrials.gov (Clini-
calTrials.gov Identifier: NCT00287768).
Role of the funding source
JACCRO and KCSG employees contributed to the study 
design and data collection and interpretation. This study 
was supported by an unconditioned grant from Sanofi K.K. 
Japan. Sanofi K.K. Japan had no role in the study design, 
data collection, analysis, or interpretation, or in writing 
Fig. 1  CONSORT diagram.  
OS overall survival, PFS 
progression-free survival,  
RR response rate
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the manuscript or deciding whether it would be submitted 
for publication. Masahiro Takeuchi and Masashi Fujii had 
access to the raw data. The corresponding author had full 
access to all study data and final responsibility for the deci-
sion to submit for publication.
Results
Patients’ characteristics
Between September 2005 and September 2008, a total of 
113 centers participated (97 in Japan and 16 in Korea), 
and a total of 639 patients were registered by means of the 
FLADS® system; 316 were assigned to the docetaxel plus 
S-1 group, and 323 were assigned to the S-1 alone group.
Four patients were ineligible because they did not 
have measurable or non-measurable lesions as defined by 
RECIST: two assigned to the docetaxel plus S-1 group and 
two assigned to the S-1 alone group. The intent-to-treat 
analysis thus included 635 patients, 314 in the docetaxel 
plus S-1 group and 321 in the S-1 alone group (Fig. 1). The 
baseline characteristics of the patients were similar in the 
two treatment groups (Table 1).
Efficacy
Median follow-up of intent-to-treat group (ITT) was 
11.4 months (inter-quartile range 6.21–21.2). Of 635 cases, 
582 died, 36 were still alive, and 17 were lost to follow-up. 
The median overall survival time was 12.5 months (95 % 
confidence interval (CI) 11.4–14.8) in the docetaxel plus 
S-1 group and 10.8 months (95 % CI 9.5–11.8) in the S-1 
alone group. This difference in overall survival was statisti-
cally significant (p = 0.032; hazard ratio (HR) 0.84; 95 % 
CI 0.71–0.99) (Fig. 2a). Progression-free survival also dif-
fered significantly and was 5.3 months (95 % CI 4.5–5.9) 
in the docetaxel plus S-1 group and 4.2 months in the S-1 
alone group (95 % CI 3.7–4.7; p < 0.001; HR 0.77; 95 % 
CI 0.65–0.90) (Fig. 2b). The response rate was calculated 
on the basis of the 480 (77.3 %) of the 621 patients in the 
per-protocol set. The response rate was 38.8 % (95 % CI 
32.8–45.2; complete response, 3; partial response, 89) 
among the 237 patients with measurable lesions in the 
docetaxel plus S-1 group and 26.8 % (95 % CI 21.6–32.6; 
complete response, 5; partial response, 60) among the 243 
patients with measurable lesions in the S-1 alone group. 
This difference was statistically significant (p = 0.005).
On subgroup analysis, docetaxel plus S-1 showed sig-
nificantly better overall survival than S-1 alone in patients 
with a performance status of zero, patients with non-meas-
urable lesions, patients with no lymph-node metastasis, and 
Japanese patients than in patients with performance status 
one, patients with measurable lesions, patients with lymph-
node metastasis, and Korean patients (Figs. 3, 4). Perito-
neal metastasis was found in 109 (76 %) of the 144 patients 
with non-measurable lesions.
Treatment and compliance
The median relative dose intensity was 80.4 % for doc-
etaxel and 76.0 % for S-1 in the docetaxel plus S-1 group 
and 76.2 % for S-1 in the S-1 alone group. Treatment was 
delayed in 14.5 % of the patients in the docetaxel plus S-1 
group and 4.2 % of those in the S-1 alone group. The main 
reason for treatment delays was adverse events in both 
groups. The main reason for withdrawal of treatment was 
disease progression in both groups. After withdrawal of 
Table 1  Baseline patient characteristics
ECOG PS Eastern Cooperative Oncology Group performance status
Characteristics DOC+S-1 (n = 314) S-1 (n = 321) p value
Sex
 Male 227 229 0.79
 Female 87 92
Age (years)
 Median 65 65 0.66
 Range 23–79 27–79
ECOG PS
 0 137 147 0.58
 1 177 174
Primary lesion
 − 168 163 0.49
 + 146 158
Measurable lesions
 − 72 72 0.88
 + 242 249
Diagnosis
 Advanced 260 267 0.90
 Relapse 54 54
Adjuvant chemotherapy
 − 292 297 0.82
 + 22 24
No. of organs involved
 1 96 87 0.43
 2 116 115
 ≥3 102 119
Metastasis
 Lymph nodes 215 225 0.66
 Liver 108 107 0.78
 Lung 19 28 0.20
 Bone 9 12 0.54
 Peritoneum 119 131 0.45
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the protocol treatment, second-line therapy was given to 
69.7 % of the patients in the docetaxel plus S-1 group and 
76.0 % of those in the S-1 group.
Among the Japanese patients who received second-line 
chemotherapy, 79 % were given irinotecan, cisplatin, or 
taxanes, while most of the 60 % of Korean patients who 
received second-line chemotherapy were given 5-fluoroura-
cil-based regimens.
Safety
The incidence of grade 3 or higher adverse events was 
58.1 % in the docetaxel plus S-1 group and 39.6 % in the 
S-1 alone group (p < 0.0001). The incidences of grade 3 
or higher leukopenia and neutropenia were significantly 
higher in the docetaxel plus S-1 group than in the S-1 alone 
group (p < 0.0001) and that of febrile neutropenia was sig-
nificantly higher in the docetaxel plus S-1 group than in 
the S-1 alone group (p = 0.0024; Table 2). There were two 
treatment-related deaths in the docetaxel plus S-1 group 
(0.6 %).
Discussion
Several pivotal phase III clinical trials have been performed 
in patients with advanced gastric cancer, including the 
V325 study of docetaxel plus cisplatin/5-fluorouracil by the 
Fig. 2  Kaplan–Meier esti-
mate of overall survival and 
progression-free survival. a 
Overall survival. b Progression-
free survival
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Fig. 3  Forest plot of the treat-




Fig. 4  Overall survival and progression-free survival in subgroup 
analysis. a Overall survival in the measurable population. b Overall 
survival in the non-measurable population. c Progression-free sur-
vival in the measurable population. d Progression-free survival in the 
non-measurable population
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V325 Study Group (Van Cutsem et al. 2006), a randomized 
trial of epirubicin plus cisplatin/5-fluorouracil by Cunning-
ham and co-workers (Webb et al. 1997; Waters et al. 1999; 
Ross et al. 2002), and the SPIRITS trial of S-1 plus cis-
platin by the SPRITS Trial Group (Koizumi et al. 2008). 
These trials have established the aforementioned regimens 
as standard treatments in their respective regions. All of 
these first-line regimens contain cisplatin. Our study in 
patients with advanced gastric cancer showed that adding 
docetaxel to S-1 significantly improved the overall survival, 
progression-free survival, and response rate as compared 
with S-1 alone. The survival benefit of docetaxel plus S-1 is 
particularly important, because regimens without platinum 
compounds would be a new option for the first-line treat-
ment for advanced gastric cancer.
When we first reported the interim results of this trial 
at the American Society of Clinical Oncology (ASCO) 
Gastrointestinal Symposium 2012, the primary end point 
was not yet met. However, an independent statistician 
pointed out that data on more than 20 % of the patients had 
been censored and suggested that this problem should be 
solved to accurately evaluate treatment effectiveness. We 
therefore extended follow-up to 2 years after enrollment 
of the final patient, similar to the duration of follow-up at 
the initial analysis, to confirm the outcomes of the many 
patients with censored data. There was no alpha spending 
on reanalysis.
Docetaxel is a semisynthetic taxoid anticancer drug that 
is used as monotherapy or in combination with other anti-
cancer agents to treat various cancers (Einzig et al. 1996; 
Chan et al. 1999; Shepherd et al. 2000; O’Shaughnessy 
et al. 2002; Fossella et al. 2003: Tannock et al. 2004; Mar-
tin et al. 2005; Marty et al. 2005; Posner et al. 2007). In 
the V325 study, docetaxel plus cisplatin/5-fluorouracil was 
compared with cisplatin/5-fluorouracil. The overall survival 
was significantly longer for docetaxel plus cisplatin/5-
fluorouracil (9.2 months) than for cisplatin/5-fluorouracil 
(8.6 months; p = 0.02) (Van Cutsem et al. 2006). Although 
the doses of docetaxel differed between the V325 study 
(75 mg/m2) and our study (40 mg/m2), the benefit of adding 
docetaxel was confirmed in two large randomized studies 
of V325 and our study in advanced gastric cancer (Van Cut-
sem et al. 2006).
The main toxic effect of docetaxel is myelosuppression. 
In the V325 study, the incidence of severe neutropenia was 
82 % in patients who received docetaxel plus cisplatin/5-
fluorouracil, approved in Western countries for the treat-
ment for advanced gastric cancer (Van Cutsem et al. 2006). 
Many modified regimens of docetaxel plus cisplatin/5-fluo-
rouracil with better safety profiles can be used (Roth et al. 
2007; Lorenzen et al. 2007; Tebbutt et al. 2010; Shah et al. 
2010; Inal et al. 2012). In our study, we used docetaxel in a 
dose of 40 mg/m2, which was based on the results of Japa-
nese phase I/II studies, and grade 3 or higher neutropenia 
occurred in only 29 % of the patients who received doc-
etaxel plus S-1. Because the rate of severe neutropenia was 
low in our study, the dose of docetaxel might be able to be 
increased slightly, approaching the level used in Western 
countries, but since docetaxel plus S-1 therapy was admin-
istered on an outpatient basis, our dose setting might be 
appropriate for Asian patients and is considered effective in 
terms of survival.
The tumor burden is a more important prognostic factor 
than other factors, such as performance status or whether 
the patient receives adjuvant chemotherapy. To our knowl-
edge, the present study is the first large randomized clini-
cal trial to stratify patients with advanced gastric cancer 
according to measurable or non-measurable lesions. In our 
pre-planned subgroup analysis, there was no statistically 
significant difference in overall survival between the doc-
etaxel plus S-1 group (11.7 months; n = 242) and the S-1 
alone group (10.3 months; n = 249; HR 0.90; p = 0.28) 
among patients with measurable lesions. Among patients 
with non-measurable lesions, however, the overall sur-
vival was significantly longer in the docetaxel plus S-1 
group (17.9 months; n = 72) than in the S-1 alone group 
(12.0 months; n = 72; HR 0.65; p = 0.013) (Fig. 3). In 
Table 2  Safety (adverse events)
Asterisk indicates one treatment-related death in each adverse event
Adverse drug reactions are based on CTCAE V3.0
AST aspartate aminotransferase, ALT alanine aminotransferase
Adverse event DOC+S-1 
(n = 310)
S-1 (n = 313) p value
≥Grade 3 (%) ≥Grade 3 (%)
Any 180 (58.1) 124 (39.6) <0.001
Leukopenia 68 (21.9) 8 (2.6) <0.001
Neutropenia 90* (29.0) 14 (4.5) <0.001
Platelets 5* (1.6) 2 (0.6) 0.249
Hemoglobin 36 (11.6) 25 (8.0) 0.128
AST 3 (1.0) 7 (2.2) 0.208
ALT 3 (1.0) 6 (1.9) 0.321
Bilirubin 4 (1.3) 8 (2.6) 0.251
Creatinine 1 (0.3) 2 (0.6) 0.568
Nausea 18 (5.8) 11 (3.5) 0.175
Vomiting 10 (3.2) 7 (2.2) 0.449
Diarrhea 9 (2.9) 15 (4.8) 0.221
Stomatitis 13 (4.2) 5 (1.6) 0.053
Anorexia 48 (15.5) 37 (11.8) 0.183
Fatigue 18 (5.8) 15 (4.8) 0.572
Rash 3 (1.0) 6 (1.9) 0.321
Febrile neutropenia 9 (2.9) 0 (0) 0.002
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an exploratory subgroup analysis of the SPIRITS trial, 
S-1 plus cisplatin was associated with a higher benefit in 
patients with non-target tumors than in those with target 
tumors (Koizumi et al. 2008).
For pre-stratified measurable tumors, the overall sur-
vival benefit of docetaxel plus S-1 was not significant, 
but progression-free survival was significantly better 
with docetaxel plus S-1 (4.7 months) than with S-1 alone 
(3.9 months; HR 0.82; p = 0.03). This finding might be 
attributed to the notion that overall survival time is influ-
enced by effective second-line chemotherapy, whereas 
progression-free survival is not. For patients with measur-
able tumors, more active regimens for combination chemo-
therapy, such as triplet regimens or regimens including new 
biological agents, should be investigated.
The present study was conducted in Japan and Korea, and 
the recommended dose of S-1 differs between Asian patients 
(80 mg/m2) and those in Western countries (50 mg/m2) 
(Ajani et al. 2010). Our results therefore cannot be extrapo-
lated to all patients with gastric cancer. However, docetaxel 
plus S-1 therapy appears to be a promising, non-platinum-
based treatment option for patients with gastric cancer in 
East Asia, which accounts for about 60 % of all cases of gas-
tric cancer in the world. The results of our study may also 
provide important clues to the development of S-1-based, 
non-platinum regimens in Europe and North America.
In conclusion, docetaxel plus S-1 therapy is expected 
to become an important treatment option for patients with 
advanced gastric cancer, particularly those with compro-
mised renal function or who want to receive chemotherapy 
on an outpatient basis.
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Ohta; Iwate Medical University—K. Koeda; Jichi Medical 
University Hospital—M. Hyodo, Y. Hosoya; Jikei Univer-
sity School of Medicine—T. Sasaki; Kagoshima Univer-
sity Graduate School of Medical and Dental Sciences—
A. Nakajo; Kanazawa Medical University—T. Kosaka; 
Kanazawa University—T. Fujimura; Kaneda Hospital—M. 
Uno; Keiju Medical Center—T. Kamata; Kinki Central 
Hospital—K. Kobayashi; Kinki University School of Med-
icine—M. Miyazaki, T. Sato, W. Okamoto; Kitasato Uni-
versity East Hospital—K. Higuchi, S. Tanabe, T. Sasaki, 
W. Koizumi; Kobe University Hospital—Y. Fujishima; 
Kochi Health Sciences Center—A. Tsuji; Kouseiren Taka-
oka Hospital—T. Hara; Kumamoto University Graduate 
327J Cancer Res Clin Oncol (2014) 140:319–328 
1 3
School of Medical Sciences—M. Watanabe; Kurume Uni-
versity, School of Medicine—A. Keishiro; Kushiro City 
General Hospital—A. Goto; Kyorin University Hospital—
O. Yanagida; Kyoto University Hospital—S. Matsumoto; 
Kyushu Central Hospital—K. Sumiyoshi; Kyusyu Uni-
versity Graduate School of Medicine—H. Saeki; Matsuy-
ama Shimin Hospital—R. Watanabe, S. Yunoki; Minoh 
City Hospital—S. Iijima; Morioka Red Cross Hospital—
Y. Sugimura; Nagano Municipal Hospital—K. Okita, Y. 
Munakata; Nagasaki University Graduate School of Bio-
medical Science—S. Hidaka; Nakadori General Hospi-
tal—H. Andoh; National Center for Global Health and 
Medicine—J. Akiyama; National Hospital Organization 
Hokkaido Cancer Center—Y. Takahashi; National Hospi-
tal Organization Kure Medical Center and Chugoku Can-
cer Center—N. Hatanaka; National Hospital Organization 
Nagasaki Medical Center—T. Nakata; National Hospi-
tal Organization Nagoya Medical Center—M. Kataoka; 
National Kyushu Cancer Center—H. Ariyama, T. Esaki; 
Nihon University School of Medicine—M. Kochi; Nip-
pon Steel Yawata Memorial Hospital—R. Ohta; Osaka 
City University Graduate School of Medicine—B. Nakata; 
Osaka General Medical Center—K. Nishikawa; Rinku 
General Medical Center, Izumisano Municipal Hospital—
H. Mizuno, M. Izukura, T. Mizushima; Saga University—
M. Tanaka; Saiseikai Shiga Prefectural Hospital—T. Shige-
matsu; SaiseikaiYokohamashi Tobu Hospital—T. Egawa; 
Sakai Municipal Hospital—T. Kishimoto; Sapporo Medi-
cal University School of Medicine—T. Nobuoka; Shimane 
University School of Medicine—N. Hirahara; Showa Uni-
versity Fujigaoka Hospital—H. Nemoto; Showa University 
Hospital—K. Yamazaki, Y. Tajima; Social Insurance Chuo 
General Hospital, M. Shibasaki; St.Marianna University 
School of Medicine—T. Tsuda; St.Marianna University 
Yokohama-city Seibu Hospital—A. Hanai, K. Sumiyoshi, 
M. Kimura; Surugadai Nihon University Hospital—K. 
Hagiwara; Teikyo University School of Medicine—K. 
Iwasaki; Tohoku Rosai Hospital—H. Musha; Tohoku 
University—Y. Kakudo; Tokai University Hospital—K. 
Nabeshima; Toki Municipal General Hospital—T. Oiwa; 
Tokushima Red Cross Hospital—H. Ishikura, H. Okitsu; 
Tokyo Medical and Dental University—M. Inokuchi, S. 
Ooka; Tokyo Medical University—S. Hoshino; Tokyo Met-
ropolitan Cancer and Infectious Diseases Center Koma-
gome Hospital—Y. Iwasaki; Toranomon Hospital—T. 
Iizuka; Tottori University Faculty of Medicine—H. Saito, 
S. Tatebe; Toyonaka Municipal Hospital—J. Fujiita; Uni-
versity of Occupational and Environmental Health—A. 
Higure, K. Hirata; Yamagata Prefectural Central Hospi-
tal—H. Saito, K. Suzuki, T. Matsuda; Yamanashi Prefec-
tural Central Hospital—M. Hada; Yokohama Municipal 
Citizen’s Hospital—M. Takahashi; (KCSG group in South 
Korea) Chungnam National University Hospital—S. Y. 
Kim; Department of Internal Medicine St. Mary’s Hospi-
tal—I. S. Woo; Hallym University Sacred Heart Hospital—
D. Y. Zang; Hanyang University Guri Hospital—J. H. Choi; 
Inha University—M. H. Lee; Inje University Seoul Paik 
Hospital—H. G. Lee; Kangbuk Samsung Hospital—S. S. 
Lee; Korea University Anam Hospital—Y. H. Kim; Korea 
University Guro Hospital—J. S. Kim; Seoul National Uni-
versity Bundang Hospital—G. W. Lee; Seoul National Uni-
versity Hospital—T. Y. Kim; St. Vincent’s Hospital—H. 
K. Kim; Wonju Christian Hospital—J. I. Lee, K. Y. Shim; 
Yeungnam University Hospital—K. H. Lee; Yong Dong 
Severance Hospital—H. C. Jeung; Yonsei University Col-
lege of Medicine—S. J. Kim.
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